IDXX icon

Idexx Laboratories

641.35 USD
-4.20
0.65%
At close Aug 25, 4:00 PM EDT
After hours
641.35
+0.00
0.00%
1 day
-0.65%
5 days
0.53%
1 month
13.48%
3 months
24.17%
6 months
39.47%
Year to date
56.87%
1 year
32.49%
5 years
67.05%
10 years
817.00%
 

About: Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Employees: 11,000

0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

119% more first-time investments, than exits

New positions opened: 195 | Existing positions closed: 89

28% more capital invested

Capital invested by funds: $30.9B [Q1] → $39.4B (+$8.53B) [Q2]

22% more funds holding in top 10

Funds holding in top 10: 18 [Q1] → 22 (+4) [Q2]

7% more funds holding

Funds holding: 1,124 [Q1] → 1,204 (+80) [Q2]

1% more repeat investments, than reductions

Existing positions increased: 415 | Existing positions reduced: 409

0.67% more ownership

Funds ownership: 90.76% [Q1] → 91.44% (+0.67%) [Q2]

19% less call options, than puts

Call options by funds: $84.6M | Put options by funds: $104M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$540
16%
downside
Avg. target
$656
2%
upside
High target
$765
19%
upside

5 analyst ratings

positive
60%
neutral
40%
negative
0%
Morgan Stanley
Erin Wright
19%upside
$765
Overweight
Maintained
15 Aug 2025
Piper Sandler
David Westenberg
9%upside
$700
Neutral
Maintained
11 Aug 2025
JP Morgan
Chris Schott
5%upside
$675
Overweight
Maintained
4 Aug 2025
Leerink Partners
Daniel Clark
6%downside
$600
Outperform
Maintained
17 Jul 2025
Stifel
Jonathan Block
16%downside
$540
Hold
Maintained
2 Jul 2025

Financial journalist opinion

Based on 24 articles about IDXX published over the past 30 days

Positive
Zacks Investment Research
19 hours ago
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
Positive
Zacks Investment Research
23 hours ago
IDEXX Gains 56.2% in a Year: What's Driving the Rally?
IDXX shares surge 56.2% in a year, fueled by strong diagnostics growth, cloud software gains and an upbeat 2025 outlook.
IDEXX Gains 56.2% in a Year: What's Driving the Rally?
Positive
Zacks Investment Research
3 days ago
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Positive
Zacks Investment Research
2 weeks ago
Is Idexx (IDXX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Idexx (IDXX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Positive
Zacks Investment Research
2 weeks ago
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Neutral
Seeking Alpha
2 weeks ago
Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts
Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses, guidance cuts, and Medicare Advantage mispricing, despite its long-term potential to restore profitability. Thermo Fisher and argenx detracted from performance amid macro headwinds and lower-than-expected sales, but we retain conviction in their long-term prospects.
Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts
Positive
Zacks Investment Research
2 weeks ago
Why Idexx Laboratories (IDXX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Idexx Laboratories (IDXX) is a Top Momentum Stock for the Long-Term
Positive
Investopedia
3 weeks ago
S&P 500 Gains and Losses Today: Retail Sector Stocks Rise Amid Rate Cut Hopes
Major U.S. equities indexes pushed higher at the top of the new trading week, bouncing back from declines posted ahead of the weekend. Although weaker-than-expected jobs data released on Friday raised concerns about the resilience of the economy, the slowdown in hiring and uptick in unemployment could add to the case for upcoming interest-rate cuts by the Federal Reserve.
S&P 500 Gains and Losses Today: Retail Sector Stocks Rise Amid Rate Cut Hopes
Neutral
Seeking Alpha
3 weeks ago
IDEXX Laboratories, Inc. (IDXX) Q2 2025 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jonathan J. Mazelsky - President, CEO & Director Conference Call Participants Christopher Thomas Schott - JPMorgan Chase & Co, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Erin Elizabeth Wilson Wright - Morgan Stanley, Research Division Jonathan David Block - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division Navann Ty Dietschi - BNP Paribas Exane, Research Division Ryan Scott Daniels - William Blair & Company L.L.C.
IDEXX Laboratories, Inc. (IDXX) Q2 2025 Earnings Call Transcript
Neutral
CNBC Television
3 weeks ago
Final Trades: Delta Air Lines, Tesla, Idexx Lab and the IYF
The Investment Committee gives you their top stocks to watch for the second half.
Final Trades: Delta Air Lines, Tesla, Idexx Lab and the IYF
Charts implemented using Lightweight Charts™